What 14 Analyst Ratings Have To Say About Sarepta Therapeutics

1 day ago · Price Targets: Gaining insights, analysts provide estimates for the future value of Sarepta Therapeutics's stock. This comparison reveals trends in analysts' expectations over time.

$164.08
OFF

12 Analysts Have This To Say About Sarepta Therapeutics

2 weeks from now

May 20, 2024 · Analysts have set 12-month price targets for Sarepta Therapeutics, revealing an average target of $164.08, a high estimate of $185.00, and a low estimate of $128.00.

nasdaq.com

$182
OFF

Expert Outlook: Sarepta Therapeutics Through The Eyes Of 25 …

2 weeks from now

Jul 1, 2024 · In the assessment of 12-month price targets, analysts unveil insights for Sarepta Therapeutics, presenting an average target of $182.8, a high estimate of $235.00, and a low …

businessinsider.com

$168.79
OFF

Analyst Expectations For Sarepta Therapeutics's Future

2 weeks from now

Nov 25, 2024 · Analysts have set 12-month price targets for Sarepta Therapeutics, revealing an average target of $168.79, a high estimate of $205.00, and a low estimate of $80.00.

benzinga.com

$175.72
OFF

Sarepta Therapeutics (NASDAQ:SRPT) Stock, Analyst Ratings

2 weeks from now

Sarepta Therapeutics Inc has a consensus price target of $175.72 based on the ratings of 25 analysts. The high is $230 issued by Leerink Partners on June 24, 2024.The low is $75 issued …

benzinga.com

17%
OFF

Sarepta Therapeutics Stock Forecast - Stock Analysis

2 weeks from now

5 days ago · Sarepta Therapeutics, Inc. (SRPT) NASDAQ: SRPT · Real-Time Price · USD. Watchlist Compare. 124.79-1.48 (-1.17%) Jan 10, 2025, 4:00 PM EST - Market closed. …

stockanalysis.com

30%
OFF

Sarepta Therapeutics To Rally Around 30%? Here Are 10 Top …

2 weeks from now

Nov 7, 2024 · Cantor Fitzgerald raised the price target for Sarepta Therapeutics, Inc. SRPT from $152 to $167. Cantor Fitzgerald analyst Kristen Kluska upgradd the stock from Neutral to …

benzinga.com

1%
OFF

Wall Street Analysts Think Sarepta Therapeutics (SRPT) Could …

2 weeks from now

Nov 27, 2024 · The mean of analysts' price targets for Sarepta Therapeutics (SRPT) points to a 42.1% upside in the stock. While this highly sought-after metric has not proven reasonably …

zacks.com

95%
OFF

Wall Street Analysts See A 47.95% Upside In Sarepta Therapeutics …

2 weeks from now

Dec 13, 2024 · The consensus price target hints at a 48% upside potential for Sarepta Therapeutics (SRPT). While empirical research shows that this sought-after metric is hardly …

zacks.com

$158.87
OFF

A Glimpse Into The Expert Outlook On Sarepta Therapeutics

2 weeks from now

Dec 19, 2024 · Analysts have recently evaluated Sarepta Therapeutics and provided 12-month price targets. The average target is $158.87, accompanied by a high estimate of $205.00 and …

nasdaq.com

$148.00
OFF

HC Wainwright Reaffirms Sell Rating For Sarepta Therapeutics …

2 weeks from now

1 day ago · Finally, Guggenheim boosted their price target on Sarepta Therapeutics from $148.00 to $150.00 and gave the stock a "buy" rating in a research note on Thursday, November 7th. …

marketbeat.com

95%
OFF

Wall Street Analysts See A 47.95% Upside In Sarepta Therapeutics …

2 weeks from now

Dec 13, 2024 · Shares of Sarepta Therapeutics (SRPT) have gained 14.1% over the past four weeks to close the last trading session at $124.47, but there could still be a solid upside left in …

nasdaq.com

FAQs about What 14 Analyst Ratings Have To Say About Sarepta Therapeutics Coupon?

What is the average price target for Sarepta Therapeutics?

In the assessment of 12-month price targets, analysts unveil insights for Sarepta Therapeutics, presenting an average target of $182.8, a high estimate of $235.00, and a low estimate of $128.00. Marking an increase of 10.38%, the current average surpasses the previous average price target of $165.61. ...

How do analysts evaluate Sarepta Therapeutics?

Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Sarepta Therapeutics compared to the broader market. Price Targets: Understanding forecasts, analysts offer estimates for Sarepta Therapeutics's future value. ...

What is a Sarepta Therapeutics rating?

Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Sarepta Therapeutics compared to the broader market. ...

Should you buy Sarepta Therapeutics (SRPT) stock?

Leerink Partners analyst Joseph Schwartz has reiterated their bullish stance on SRPT stock, giving a Buy rating yesterday. Joseph Schwartz has given his Buy rating due to a combination of factors including Sarepta Therapeutics’ robust financial performance and promising future outlook. ...

Does Sarepta Therapeutics have a high debt-to-equity ratio?

Debt Management: With a high debt-to-equity ratio of 1.63, Sarepta Therapeutics faces challenges in effectively managing its debt levels, indicating potential financial strain. Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. ...

Does Sarepta Therapeutics have a good return on equity?

Return on Equity (ROE): Sarepta Therapeutics's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of -5.44%, the company may face hurdles in generating optimal returns for shareholders. ...